The American Journal of Managed Care

With Sub-Q Immunotherapy Coming, “Patient Preference Has to Be the Key”

Subcutaneous nivolumab injection marks a significant advancement in cancer therapy, offering faster administration than traditional intravenous methods. The shift to subcutaneous delivery could lead ...
Nasdaq

Alcyone Therapeutics Receives FDA IDE Approval to Initiate Clinical Study of the ThecaFlex DRxTM System for Administration of SPINRAZA® (nusinersen)

Alcyone's ThecaFlex DRx™ System is an implantable medical device in development to enable routine subcutaneous administration of therapeutics to the cerebrospinal fluid First stage of the pivotal ...
Nasdaq

Alcyone Therapeutics Announces Continued Enrollment Approval from FDA of the PIERRE Pivotal IDE Clinical Study of the ThecaFlex DRx™ System for Administration of nusinersen

LOWELL, Mass., July 31, 2024 /PRNewswire/ -- Alcyone Therapeutics Inc. (Alcyone), a clinical-stage biotechnology company pioneering next-generation precision genetic therapies and precision delivery ...
The Victoria Advocate

Portal Access, Inc. Announces the closing of $7 Million Series A Financing Round to Support FDA Approval and Limited Market Launch of Next-Generation Chemotherapy Port

MIAMI, May 27, 2025 /PRNewswire/ -- Portal Access, Inc., a medical device start-up company pioneering next-generation advanced vascular access solutions for oncology, announced the successful closing ...